Open AccessClinical Characteristics of Children With Celiac Disease Not Responding to Hepatitis B Vaccination in India
Author(s) -
Aneja Aradhana,
Lal Sadhna B.,
Sharma Arun K,
Rawat Amit,
Singh Surjit
Publication year - 2021
Publication title -
jpgn reports
Language(s) - English
Resource type - Journals
ISSN - 2691-171X
DOI - 10.1097/pg9.0000000000000046
Subject(s) - medicine , hbsag , immune system , immunology , hepatitis b , hepatitis b virus , vaccination , population , booster dose , hepatitis b vaccine , disease , immunization , virus , environmental health
Background: The immunological response to hepatitis B virus (HBV) vaccine may be suboptimal in children with celiac disease (CD), but the reasons for this are not well defined. Objectives: This study was undertaken to assess the immune response to HBV vaccine in CD children and to explore the possible factors affecting the immune response. Methods: The study population consisted of 3 groups—50 newly diagnosed CD children (group 1), 50 previously diagnosed CD children who were on gluten free diet (GFD) >3 months (group 2), and 100 age and gender matched healthy controls (group 3). The patient characteristics were recorded, and the blood samples were analyzed for HBsAg and anti‐HBs titers. The nonresponders were given a booster dose of HBV vaccine and reevaluated after 6 weeks. Results: Positive anti‐HBs response was found in 46% in newly diagnosed CD children, 60% in CD children on GFD, and 83% in healthy controls ( P < 0.001). The immune response to HBV vaccine in CD children was inferior to that in healthy children (53% vs 83%, P < 0.001). The immune response was found to be significantly affected by age at diagnosis, delay in diagnosis, type of presentation, and compliance to GFD. 44 out of 45 (97.77%) nonresponders from CD group seroconverted after a single booster dose. Conclusion: Early diagnosis and good compliance to GFD may improve the immune response to HBV vaccine in CD children. Single additional booster dose is sufficient to attain optimal immune response.